Press Releases

Compugen Discloses New Results Supporting CGEN-15052 as Novel Immune Checkpoint Target Candidate for Treatment of Cancer

Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City

Sep 16, 2015
MORE EVENTS
Banner